XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement.

On June21, 2017, we entered into an Office Lease (the Lease) with
PRII High Bluffs LLC and Collins Corporate Center Partners, LLC
(collectively, the Landlord) for approximately 23,700 square feet
of rentable space located at 12481 High Bluff Drive, San Diego,
California (the Property). The Lease is scheduled to commence on
September1, 2017 (the Commencement Date) and will terminate 60
months following the Commencement Date. The initial base monthly
rent is $98,545.90 and will increase by approximately $3,000 each
year. We may also have to pay additional rent equal to our
proportionate share of certain operating costs if such operating
costs for the Property exceed a certain amount.

A copy of the Lease is filed as Exhibit99.1 to this report and
the description of the terms of the Lease is qualified in its
entirety by reference to such exhibit.

Item 5.07 Submission of Matters to a
Vote of Security Holders.

On June22, 2017, we held our 2017 Annual Meeting of Stockholders
(Annual Meeting). As of April27, 2017, the record date for the
Annual Meeting, 46,698,731 shares of common stock were
outstanding and entitled to vote at the Annual Meeting. A summary
of the matters voted upon by stockholders at the Annual Meeting
is set forth below.

Proposal 1. Election of Directors

Our stockholders elected the five persons listed below as
directors, each to serve until our 2018 Annual Meeting of
Stockholders and until their successors are duly elected and
qualified. The final voting results are as follows:

Proposal 2. Ratification of the Selection of Independent
Registered Public Accounting Firm

Our stockholders ratified the selection by our Audit Committee of
RSM US, LLP as our independent registered public accounting firm
for the fiscal year ending December31, 2017. The final voting
results are as follows:

Proposal 3. Advisory Vote on the Compensation of the
Companys Named Executive Officers

Our stockholders approved, on an advisory (non-binding) basis,
the compensation of our named executive officers as disclosed in
our definitive proxy statement for the Annual Meeting filed with
the Securities and Exchange Commission on May1, 2017 (Proxy
Statement). The final voting results are as follows:

Xencor Inc Exhibit
EX-99.1 2 a17-15705_1ex99d1.htm EX-99.1 Exhibit 99.1   OFFICE LEASE   by and between   PRII HIGH BLUFFS LLC,…
To view the full exhibit click here
About XENCOR, INC. (NASDAQ:XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

XENCOR, INC. (NASDAQ:XNCR) Recent Trading Information

XENCOR, INC. (NASDAQ:XNCR) closed its last trading session down -0.27 at 21.69 with 461,917 shares trading hands.